Savings from the introduction of BPaL and BPaLM regimens at the country level
Authors:
Open Access
- 1 July 2024
- journal article
- Published by International Union Against Tuberculosis and Lung Disease in IJTLD OPEN
- Vol. 1 (7) , 314-319
Abstract
SUMMARY: BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a country switches from current standard-of-care treatment regimens to BPaL/BPaLM. METHODOLOGY: Country data from national TB programmes (NTP) are used to calculate the costs for all regimens and treatment outcomes. Where BPaL/BPaLM is not currently used, clinical trial outcomes data are used to estimate cost-effectiveness. DALYs are calculated using the Global Burden of Disease (GBD) database. RESULTS: We present the results of four countries that have used the tool and shared their data. When shorter and longer regimens are replaced with BPaL/BPaLM, the savings per patient treated in Pakistan, the Philippines, South Africa, and Ukraine are $746, $478, $757, and $2,636, respectively. An increased number of patients would be successfully treated with BPaL/BPaLM regimens, with 411, 1,025, 1,371 and 829 lives saved and 20,179, 27,443, 33,384 and 21,924 DALYs averted annually in the four countries, respectively. CONCLUSION: Through BPaL/BPaLM regimens, drug-resistant TB treatment has become more effective, shorter, less burdensome for patients, cheaper for both health systems and patients, and saves more lives.Keywords
This publication has 9 references indexed in Scilit:
- Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trialThe Lancet Respiratory Medicine, 2023
- Post-tuberculosis sequelae in children and adolescents: a systematic reviewThe Lancet Infectious Diseases, 2023
- A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine, 2022
- Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosisPLOS Global Public Health, 2022
- Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant TuberculosisNew England Journal of Medicine, 2022
- Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosisBMJ Global Health, 2022
- WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update2022
- Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesBMJ Open, 2021
- “This is not my body”: Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosisPLOS ONE, 2021